Joining us for this discussion is a fellow board-certified obesity medicine physician Dr. Marilyn Galindo, founder of Leon Springs Obesity Medicine.
If you're managing obesity, PCOS, prediabetes, metabolic syndrome, or type 2 diabetes, you've probably heard a lot of buzz lately about weight loss medications. The good news? The landscape is about to get even better. Several promising new options are on the horizon — and as an obesity medicine physician, I want to make sure you have accurate, evidence-based information before these medications hit your pharmacy.
Let's break down three of the most exciting options coming soon with Dr. Marilyn Galindo.
1. High-Dose Semaglutide (Wegovy 7.2 mg) — More Weight Loss for Those Who Need It
You may already be familiar with Wegovy (semaglutide), one of the most commonly prescribed FDA-approved weekly injectable medications for obesity. The current maximum approved dose is 2.4 mg per week, which helps most patients lose between 13–15% of their body weight on average.
But what about patients who need to lose closer to 20% — or more?
Clinical trials are now studying semaglutide at doses up to 7.2 mg per week. Early results are encouraging:
- On average, patients lost approximately 18–20% of their body weight
- About 30% of patients lost 25% or more of their body weight
- The medication is the same GLP-1 receptor agonist your body already responds to — just at a higher dose
This is particularly relevant for patients who:
- Have responded well to semaglutide but haven't yet reached their weight loss goals at 2.4 mg
- Tolerate semaglutide better than tirzepatide (Zepbound/Mounjaro)
- Want to continue optimizing results before trying a different medication class
What about side effects? Higher doses do carry a greater chance of nausea and constipation — the most common GLP-1 side effects. There's also a higher rate of a pins-and-needles skin sensation at this dose. That said, tolerability varies significantly from person to person, and working with an obesity medicine specialist who knows how to titrate dosing slowly and individualize your care can make a real difference.
When could it be available? Potentially as early as spring 2025 — we'll keep our patients informed as updates emerge.
2. CagriSema — A New Combination Medication With Promising Results for Weight Maintenance
CagriSema is a once-weekly injectable combination of:
- Semaglutide (the same GLP-1 hormone as Wegovy)
- Cagrilintide, a synthetic version of amylin — a hormone made in the pancreas that helps regulate fullness and blood sugar
Together, these two hormones target appetite and metabolism through complementary pathways, which is why early trials are showing average weight loss results comparable to tirzepatide — around 20% of body weight.
Why the Amylin Component Matters
One of the most exciting aspects of CagriSema is what the amylin analog may do beyond weight loss: it may help prevent the drop in metabolic rate that typically happens as you lose weight.
Here's the challenge we face in obesity medicine: when the body loses weight, it compensates by lowering its resting metabolic rate, which makes maintaining weight loss incredibly difficult — even with continued medication. If CagriSema can blunt that compensatory slowdown, it would be a powerful tool not just for losing weight, but for keeping it off long-term.
This is still being studied in longer trials, but the early science is promising.
Who Might Benefit Most?
- Patients currently on semaglutide who have plateaued at 2.4 mg
- Patients who have achieved their goal weight and are focused on maintenance
- Patients for whom weight maintenance has historically been the hardest part of the journey
When could it be available? Estimated availability is late 2026 to early 2027.
3. Orforglipron — A Flexible Daily Oral GLP-1 Option
Not everyone wants a weekly injection — and that's completely valid. Orforglipron is an oral GLP-1 receptor agonist from Eli Lilly currently in late-stage development, and it offers several advantages that set it apart from existing oral options.
Why This Is Different From Oral Wegovy
Currently, the only FDA-approved oral semaglutide (Rybelsus/oral Wegovy) has strict requirements: it must be taken on an empty stomach, with a small amount of water, and you can't eat or take other medications for at least 30 minutes afterward. For many patients — especially those already taking multiple morning medications — this just isn't realistic.
Orforglipron can be taken with or without food, and alongside other medications. That's a significant step forward in accessibility and ease of use.
What to Expect
- Average weight loss of approximately 10% of body weight — lower than injectables, but meaningful for many patients
- Daily dosing with a simple pill — no injection, no sharps disposal, less packaging waste
- More flexibility around surgery or procedures (since the daily effect wears off within 24 hours, pausing it is much simpler than managing a weekly injectable)
- Likely lower cost than injectable options, making it more accessible for more patients
How I See Using This in Practice
Orforglipron may be ideal for patients who:
- Prefer oral medication or have needle aversion
- Need only 10% weight loss to meet their health goals
- Have already reached their target weight on an injectable GLP-1 and want a simpler, potentially more affordable long-term maintenance option
In fact, one study looked at patients who had already achieved their goal weight on tirzepatide or semaglutide and then switched to orforglipron — after one year, they had not regained weight. That's a compelling maintenance strategy.
When could it be available? It is currently under FDA review, with a decision expected in 2025.
A Note on Safety: One Medication That Is NOT Ready
You may have also heard about retatrutide, sometimes called the "triple G" on social media, because it targets three hormone receptors (GLP-1, GIP, and glucagon). Clinical trial results have been remarkable — weight loss approaching bariatric surgery levels — and it may be approved by the FDA by end of 2025.
However, retatrutide is not currently FDA-approved, and it should not be purchased or used outside of a clinical trial. If someone is offering to sell or prescribe it to you right now, that is a serious red flag. Unregulated compounded versions of unapproved medications carry unknown risks. Please talk to your physician before starting any new medication you've seen discussed on social media.
Why Working With an Obesity Medicine Specialist Matters
All of these medications work best when paired with individualized, expert medical care. Research shows that patients managed by obesity medicine specialists are significantly more likely to tolerate GLP-1 medications long-term — because specialists take the time to:
- Titrate doses slowly and thoughtfully based on your response
- Educate you on side effects and how to manage them before they become serious
- Adjust your treatment plan as your health evolves
- Help you understand that weight management is a chronic condition that deserves the same ongoing treatment as hypertension or diabetes
Obesity is associated with more than 200 metabolic conditions — including PCOS, prediabetes, type 2 diabetes, metabolic syndrome, fatty liver disease, and sleep apnea. Treating it effectively isn't just about the number on the scale. It's about your long-term health.
Ready to Explore Your Options?
At Missouri Metabolic Health, I provide personalized, evidence-based care for adults managing obesity, PCOS, prediabetes, metabolic syndrome, and type 2 diabetes. As a board-certified Family Medicine and Obesity Medicine physician, I combine lifestyle optimization with safe and effective medical treatment — because you deserve care that treats the whole picture.
If you're curious about whether any of these new medications might be right for you, or if you're not sure where to start, I'd love to connect.
This post is for general educational purposes only and does not constitute personalized medical advice. Please speak with your healthcare provider about what treatment options are appropriate for your individual situation.
view + leave comments . . .